About: Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background Adipocyte-fatty acid binding prottein (A-FABP) is a circulating protein expressed in adipocytes and macrophages. Several recent studies deminstrated that A-FABP might be involed in the pathogenesis of metabolic syndrome, particularly in dyslipidaemia, insulin resistance and atherosclerosis. The aim of this study was to investigete the influence of atorvastatin treatment (20 mg day for 3 months) on serum A-FABP value in subjects with hyperlipidaemia. Conclusions In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions. Background Adipocyte-fatty acid binding prottein (A-FABP) is a circulating protein expressed in adipocytes and macrophages. Several recent studies deminstrated that A-FABP might be involed in the pathogenesis of metabolic syndrome, particularly in dyslipidaemia, insulin resistance and atherosclerosis. The aim of this study was to investigete the influence of atorvastatin treatment (20 mg day for 3 months) on serum A-FABP value in subjects with hyperlipidaemia. Conclusions In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions. (en) A-FABP je cirkulující protein exprimovaný v adipocytech v makrofázích. Současné studie uvádějí, že A-FABP by mohl mít roli v patogenezi metabolického syndromu, především v rozvoji dyslipidémie, inzulínové rezistence a aterosklerózy. (cs)
Title	Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia (en) Léčba atorvastatinem redukuje sérové hodnoty %22adipocyte-fatty acid binding%22 protteinu u pacientů s hyperlipidémií (cs)
skos:prefLabel	Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia (en) Léčba atorvastatinem redukuje sérové hodnoty %22adipocyte-fatty acid binding%22 protteinu u pacientů s hyperlipidémií (cs)
skos:notation	RIV/61989592:15110/07:00003982!RIV08-MZ0-15110___
http://linked.open.../vavai/riv/strany	637-642
http://linked.open...avai/riv/aktivita	P S
http://linked.open...avai/riv/aktivity	P(1A8250), S
http://linked.open...iv/cisloPeriodika	37
http://linked.open...vai/riv/dodaniDat	2008
http://linked.open...aciTvurceVysledku	Lichnovská, Radka Ben yahia, Rabha Janout, Vladimír Horáková, Dagmar Čížek, Luděk Janoutová, Gabriela
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	455689
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/07:00003982
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	A-FABP; atorvastatin; cholesterol; hyperlipidaemia; metabolic syndrome; treatment (en)
http://linked.open.../riv/klicoveSlovo	A-FABP atorvastatin cholesterol treatment metabolic syndrome hyperlipidaemia
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[763BFD4B7F86]
http://linked.open...i/riv/nazevZdroje	European Journal of Clinical Investigation
http://linked.open...in/vavai/riv/obor	ED
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	11 (xsd:int)
http://linked.open...vavai/riv/projekt	Frequency and Distribution of Insulin Resistance as a Risk Factor for Cardiovascular and Metabolic Diseases
http://linked.open...UplatneniVysledku	2007
http://linked.open...v/svazekPeriodika	8
http://linked.open...iv/tvurceVysledku	Horáková, Dagmar Janout, Vladimír Lichnovská, Radka Stejskal, D. Janoutová, Gabriela Čížek, Luděk Ben yahia, Rabha Karpíšek, M. Kotolová, H. Ochmanová, R. Kollar, P.
issn	0014-2972
number of pages	6 (xsd:int)
http://localhost/t...ganizacniJednotka	15110
is http://linked.open...avai/riv/vysledek of	Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software